Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways Retraction in /10.3892/or.2023.8684

Chen,Feng; Chen,Xiaochi; Yang,Deyong; Che,Xiangyu; Wang,Jianbo; Li,Xiancheng; Zhang,Zhiwei; Wang,Qifei; Zheng,Wei; Wang,Lina; Wang,Xuejian; Song,Xishuang

doi:10.3892/or.2016.4794

Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways

Retraction in: /10.3892/or.2023.8684

Authors:
- Feng Chen
- Xiaochi Chen
- Deyong Yang
- Xiangyu Che
- Jianbo Wang
- Xiancheng Li
- Zhiwei Zhang
- Qifei Wang
- Wei Zheng
- Lina Wang
- Xuejian Wang
- Xishuang Song
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: May 9, 2016 https://doi.org/10.3892/or.2016.4794
Pages: 165-172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is the most common malignancy of the urinary system and is also one of the 10 most common cancers of the human body. Currently, clinical treatment of bladder cancer mainly utilizes partial or total cystectomy, supplemented by conventional chemotherapy. However, such treatment has not fully improved the prognosis of patients and is associated with various side effects. Studies have found that flavonoids extracted from plants can be used in radiotherapy and chemotherapy for the prevention of postoperative recurrence and metastasis but also alone for the treatment of advanced tumors. Both applications can ameliorate clinical symptoms, improve the quality of life, and prolong the survival of patients. Based on the above information, the present study investigated the effect of isoquercitrin, a type of flavonoid found in Bidens pilosa L. extracts, on bladder cancer progression, with the goal of understanding the biological characteristics of isoquercitrin by which it participates in bladder cancer progression. Using in vitro experiments, we found that therapeutic doses of isoquercitrin significantly inhibited cell proliferation and induced apoptosis in human bladder cancer cells and that the cell cycle was arrested in the G1 phase. Isoquercitrin inhibited phosphatidylinositol 3-kinase (PI3K) and Akt phosphorylation expression levels, thus inhibiting proliferation and inducing apoptosis in the cancer cells. In addition, we found that isoquercitrin reduced protein kinase C (PKC) protein expression levels in the human bladder cancer cell lines. We also showed via in vivo experiments that isoquercitrin inhibited xenograft tumor growth in nude mice. In conclusion, our study confirmed that isoquercitrin inhibits bladder cancer progression in vivo and demonstrated that the molecular mechanism of this inhibition may be closely associated with the PI3K/Akt and PKC signaling pathways.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Dahm P and Gschwend JE: Malignant non-urothelial neoplasms of the urinary bladder: A review. Eur Urol. 44:672–681. 2003. View Article : Google Scholar : PubMed/NCBI
4	Yu B, Zhou J, Cai H, Xu T, Xu Z, Zou Q and Gu M: Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: A single-site experience. BMC Urol. 15:32015. View Article : Google Scholar : PubMed/NCBI
5	Wu WY, Hou JJ, Long HL, Yang WZ, Liang J and Guo DA: TCM-based new drug discovery and development in China. Chin J Nat Med. 12:241–250. 2014.PubMed/NCBI
6	Qiu X and Jia J: Research advances on TCM anti-tumor effects and the molecular mechanisms. J Cancer Res Ther. 10(Suppl 1): 8–13. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hsiao WL and Liu L: The role of traditional Chinese herbal medicines in cancer therapy - from TCM theory to mechanistic insights. Planta Med. 76:1118–1131. 2010. View Article : Google Scholar : PubMed/NCBI
8	Chen Q, Li P, Li P, Xu Y, Li Y and Tang B: Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway. Oncol Rep. 33:840–848. 2015.
9	Amado NG, Predes D, Fonseca BF, Cerqueira DM, Reis AH, Dudenhoeffer AC, Borges HL, Mendes FA and Abreu JG: Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway. J Biol Chem. 289:35456–35467. 2014. View Article : Google Scholar : PubMed/NCBI
10	Valentová K, Vrba J, Bancířová M, Ulrichová J and Křen V: Isoquercitrin: Pharmacology, toxicology, and metabolism. Food Chem Toxicol. 68:267–282. 2014. View Article : Google Scholar : PubMed/NCBI
11	Huang G, Tang B, Tang K, Dong X, Deng J, Liao L, Liao Z, Yang H and He S: Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway. Oncol Rep. 31:2377–2384. 2014.PubMed/NCBI
12	Amado NG, Cerqueira DM, Menezes FS, da Silva JF, Neto VM and Abreu JG: Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization. Anticancer Drugs. 20:543–552. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ran J, Wang Y, Zhang W, Ma M and Zhang H: Research on the bioactivity of isoquercetin extracted from marestail on bladder cancer EJ cell and the mechanism of its occurrence. Artif Cells Nanomed Biotechnol. 4:1–6. 2015. View Article : Google Scholar
14	Peng Y, Li L, Huang M, Duan C, Zhang L and Chen J: Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Cell Signal. 26:2782–2792. 2014. View Article : Google Scholar : PubMed/NCBI
15	Gong WY, Wu JF, Liu BJ, Zhang HY, Cao YX, Sun J, Lv YB, Wu X and Dong JC: Flavonoid components in Scutellaria baicalensis inhibit nicotine-induced proliferation, metastasis and lung cancer-associated inflammation in vitro. Int J Oncol. 44:1561–1570. 2014.PubMed/NCBI
16	Chen YJ, Cheng YJ, Hung AC, Wu YC, Hou MF, Tyan YC and Yuan SS: The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol Oncol. 131:734–743. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang CZ, Calway TD, Wen XD, Smith J, Yu C, Wang Y, Mehendale SR and Yuan CS: Hydrophobic flavonoids from Scutellaria baicalensis induce colorectal cancer cell apoptosis through a mitochondrial-mediated pathway. Int J Oncol. 42:1018–1026. 2013.PubMed/NCBI
18	Fotso AF, Longo F, Djomeni PD, Kouam SF, Spiteller M, Dongmo AB and Savineau JP: Analgesic and antiinflammatory activities of the ethyl acetate fraction of Bidens pilosa (Asteraceae). Inflammopharmacology. 22:105–114. 2014. View Article : Google Scholar
19	Yang QH, Yang J, Liu GZ, Wang L, Zhu TC, Gao HL and Kou XG: Study on in vitro anti-tumor activity of Bidens bipinnata L. extract. Afr J Tradit Complement Altern Med. 10:543–549. 2013.PubMed/NCBI
20	Maggioni D, Biffi L, Nicolini G and Garavello W: Flavonoids in oral cancer prevention and therapy. Eur J Cancer Prev. 24:517–528. 2015. View Article : Google Scholar
21	Ma TT, Xie J, Zhang QL, Xu H, Li J and Chen FH: Analysis of fingerprint and bioactive components of Bidens biternata by HPLC. Zhong Yao Cai. 35:892–896. 2012.In Chinese. PubMed/NCBI
22	Zhong MM, Chen FH, Yuan LP, Wang XH and Wu FR: Study on the property of adsorption and separation of the macroporous resins for total flavonoids of Bidens bipinnata L. Zhong Yao Cai. 30:338–341. 2007.In Chinese. PubMed/NCBI
23	Zhang X, Han C and He J: Research progress of oncogene and tumor suppressor gene in bladder cancer. Panminerva Med. 57:191–200. 2015.PubMed/NCBI
24	Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
25	Fabregat I, Roncero C and Fernández M: Survival and apoptosis: A dysregulated balance in liver cancer. Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
26	Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, et al: Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer. 13:5322013. View Article : Google Scholar : PubMed/NCBI
27	Kumar S and Vaux DL: Apoptosis. A cinderella caspase takes center stage. Science. 297:1290–1291. 2002. View Article : Google Scholar : PubMed/NCBI
28	Dewson G and Kluck RM: Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci. 122:2801–2808. 2009. View Article : Google Scholar : PubMed/NCBI
29	Fombonne J, Bssey PA, Guix C, Sadoul R, Thibert C and Mehlen P: Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc Natl Acad Sci USA. 109:10510–10515. 2012. View Article : Google Scholar : PubMed/NCBI
30	Rew DA and Wilson GD: Cell production rates in human tissues and tumours and their significance. Part II: Clinical data. Eur J Surg Oncol. 26:405–417. 2000. View Article : Google Scholar : PubMed/NCBI
31	Kazi A and Dou QP: Cell cycle and drug sensitivity. Methods Mol Med. 111:33–42. 2005.PubMed/NCBI
32	Carneiro BA, Meeks JJ, Kuzel TM, Saranti M, Abdulkadir SA and Giles FJ: Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 41:170–178. 2015. View Article : Google Scholar
33	Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M and Nawroth R: Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer. 111:2103–2113. 2014. View Article : Google Scholar : PubMed/NCBI
34	Moon G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS and Cheon J: NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 45:1027–1035. 2014.
35	Bartholomeusz C and Gonzalez-Angulo AM: Targeting the PI3K signaling pathway in cancer therapy. Expert opin Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
36	Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour biol. 36:383–391. 2015. View Article : Google Scholar
37	Liu J, Kong CZ, Gong DX, Zhang Z and Zhu YY: PKC α regulates netrin-1/UNC5B-mediated survival pathway in bladder cancer. BMC Cancer. 14:932014. View Article : Google Scholar